TY - JOUR ID - 79153 TI - 5-Year Survival Rates and Prognostic Factors in Patients with Synchronus and Metachronus Breast Cancer from 2010 to 2015 JO - Asian Pacific Journal of Cancer Prevention JA - APJCP LA - en SN - 1513-7368 AU - Sarveazad, Arash AU - Babahajian, Asrin AU - shamsadin, Jebreil AU - Bahardoust, Mansour AD - Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran. AD - Liver and Digestive Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran. AD - Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical science, Bandar Abbas, Iran. Y1 - 2018 PY - 2018 VL - 19 IS - 12 SP - 3489 EP - 3493 KW - breast cancer KW - survival KW - Metastasis KW - clinical stage KW - Iran DO - 10.31557/APJCP.2018.19.12.3489 N2 - Introduction: Currently breast (BC) cancer is a serious medical problem in all countries of the world. Survivaldepends on many factors. The present study focused on 5-year survival and its related factors in patients with BC inIran. Material and methods. The present analytical retrospective study was performed (from March 2010 until March2015) on patients with BC followed for at least 6 months. The main variables assessed were tumor size, grade of lymphnode involvement, metastasis, stage, history, human epidermal growth factor receptor expression, and tumor origin.Analysis of survival was accomplished using the Kaplan- Meier method. Results: Some 351 (80.2%) of the total of438 individuals had unilateral and 87(19.8%) had bilateral cancer, 28 (35.6%) of the latter being synchronous and56(64.4%) metachronous. Mean duration of follow-up was 47.44±28.19 months, during which 61 (17.3%) patientswith unilateral and 18 with bilateral cancer eventually died. The 5-year survival rate in patients with unilateral BC wassignificantly higher than those with bilateral BC (Log-rank Test chi2= 3.11, p=0.032). In addition, with metachronouscases, the survival rate was 64.2% in comparison with 51.6% for synchronous BCs. Survival rate was significantly(p value =0.038) higher with metachronous than with synchronous cancers (Log-rank Test chi2=3.54, p=0.038). Thehighest survival rate was reported for BCs originating from lobule tissue and the lowest rate examples of interstitialtissue origin (Log-rank Test chi2=11.54, p=0.0001). Patients with earl stage lesions (M1) survived longer than withother stages (Log-rank Test chi2= 9.55, p=0.001). Conclusion: In this study, most women with BC had a positivefamily history and were married. The 5-year survival rate was lower with advanced stages of cancer. According to ourfindings, survival rates might improve if patients undergo screening and diagnosis is made at an early stage of the disease. UR - https://journal.waocp.org/article_79153.html L1 - https://journal.waocp.org/article_79153_8d01a770aed3be4954e47f90a1ad3be8.pdf ER -